Qualitative /Methylation-Specific Multiplex Ligation-Dependent Probe Amplification (MS-MLPA)
- Preferred initial diagnostic test for AS or PWS
- Use to establish a diagnosis in individuals with clinical symptoms
- Prenatal testing for AS or PWS to identify cases resulting from molecular mechanisms that produce abnormal methylation patterns
Angelman syndrome (AS) and Prader-Willi syndrome (PWS) are complex neurodevelopmental disorders characterized by developmental delay and cognitive disability, as well as symptoms unique to each disorder (eg, unique happy demeanor in AS, excessive eating in PWS). Both conditions are linked to loss of function of genes in the 15q11.2-q13 region.
Disease Overview
Prevalence
Age of Onset
Genetics
Genes
15q11.2-q13 region
Etiologies
- Deletion of 15q11.2-q13 (AS: maternal; PWS: paternal)
- Uniparental disomy (UPD) for chromosome 15 (AS: paternal; PWS: maternal)
- Imprinting center defect
- Unbalanced chromosome translocation
- UBE3A gene mutation (AS only)
- Unidentified (AS only)
For more information about the underlying mechanisms of AS and PWS, refer to the ARUP Consult Angelman Syndrome and Prader-Willi Syndrome topic.
Prenatal Screening
- Prenatal testing is recommended for subsequent pregnancies of couples who have a previous child with AS or PWS.
- Parental testing does not exclude somatic and/or germline mosaicism.
- Testing of chorionic villus samples is not recommended as methylation may be incomplete in early embryonic development.
Test Interpretation
Clinical Sensitivity
Analytic Sensitivity
99% for PWS and AS
Results
Finding | Interpretation |
---|---|
Maternally contributed AS/PWS critical region only, with normal copy number |
|
Maternally contributed AS/PWS critical region only, with abnormal copy number consistent with deletion |
|
Paternally contributed AS/PWS critical region only, with normal copy number |
|
Paternally contributed AS/PWS critical region only, with abnormal copy number consistent with deletion |
|
Paternally and maternally contributed AS/PWS critical regions detected, with abnormal copy number consistent with duplication |
This assay is not validated to detect increased copy number of 15q11.2-q13 or determine parent of origin for duplications |
aAlters recurrence risk. Refer to the ARUP Consult Angelman Syndrome and Prader-Willi Syndrome topic for more information. |
Finding | Interpretation |
---|---|
Normal methylation pattern of both maternally and paternally contributed AS/PWS critical regions with normal copy number |
|
Limitations
- Disease mechanisms causing AS that do not alter methylation patterns will not be detected.
- The specific molecular mechanism responsible for abnormal methylation results cannot be determined via this test alone.
- Diagnostic errors can occur due to rare sequence variations.
- This assay is not validated to detect increased copy number of 15q11.2-q13 or determine parent of origin for duplications.
- This assay cannot distinguish between UPD and imprinting defects causative of PWS and AS.
- AS and PWS mosaicism will not be assessed by this assay.
- Interpretation of this test result may be impacted if the proband has had an allogeneic stem cell transplantation.
- Methylation patterns may not be fully established in early gestation; thus, diagnostic testing on chorionic villus samples is not recommended.
References
-
GeneReviews - Angelman Syndrome
Dagli AI, Matthews J, Williams CA. Angelman syndrome. In: Adam MP, Mirzaa GM, Pagon RA, et al, eds. GeneReviews, University of Washington; 1993-2023. [Updated: Apr 2021; Accessed: Mar 2023]
-
GeneReviews Prader-Willi Syndrome - PWS
Driscoll DJ, Miller JL, Cassidy SB, et al. Prader-Willi syndrome. In: Adam MP, Mirzaa GM, Pagon RA, et al, eds. GeneReviews, University of Washington; 1993-2023. [Updated: Mar 2023; Accessed: Mar 2023]
31235867
Beygo J, Buiting K, Ramsden SC, et al. Update of the EMQN/ACGS best practice guidelines for molecular analysis of Prader-Willi and Angelman syndromes. Eur J Hum Genet. 2019;27(9):1326-1340.
8651269
Diagnostic testing for Prader-Willi and Angelman syndromes: report of the ASHG/ACMG Test and Technology Transfer Committee. Am J Hum Genet. 1996;58(5):1085-1088.
18697869
Goldstone AP, Holland AJ, Hauffa BP, et al. Recommendations for the diagnosis and management of Prader-Willi syndrome [published correction appears in J Clin Endocrinol Metab. 2010;95(12):5465]. J Clin Endocrinol Metab. 2008;93(11):4183-4197.